Effectiveness of YCMAP (youth culturally adapted manual assisted problem solving) intervention in adolescents after self-harm in Pakistan: multicentre, randomised controlled trial
- PMID: 40940081
- PMCID: PMC12426884
- DOI: 10.1136/bmj-2024-083272
Effectiveness of YCMAP (youth culturally adapted manual assisted problem solving) intervention in adolescents after self-harm in Pakistan: multicentre, randomised controlled trial
Abstract
Objective: To evaluate the clinical effectiveness of the YCMAP intervention (Youth Culturally Adapted Manual Assisted Problem Solving) for adolescents after self-harm in Pakistan.
Design: Multicentre, randomised controlled trial that compared YCMAP with enhanced treatment as usual.
Settings: General practices, emergency departments, medical wards of participating hospitals, and community centres across Karachi, Hyderabad, Lahore, Multan, and Rawalpindi.
Participants: Adolescents with a recent history of self-harm identified at participating health centres by treating physicians between 5 November 2019 and 31 August 2021.
Intervention: The YCMAP group received up to 10 treatment sessions over three months; the intervention was based on the principles of cognitive behaviour therapy.
Main outcome measure: The primary outcome was the repetition of self-harm at 12 months after randomisation. Secondary outcomes were distress, hopelessness, suicidal ideation, and health related quality of life at three, six, nine, and 12 months after randomisation. Participants' satisfaction with the services was assessed at three and 12 months after randomisation.
Results: This trial was conducted between November 2019 and February 2023 and included 684 adolescents randomised to YCMAP (n=342) or enhanced treatment as usual (n=342). The YCMAP group had a significantly lower risk of self-harm repetition than the enhanced treatment as usual group at 12 months after randomisation (odds ratio 0.20, 95% confidence interval 0.06 to 0.70, P=0.006). YCMAP participants showed a statistically significant reduction in distress, hopelessness, and suicidal ideation at three months, but these differences were not statistically significant at 12 months. YCMAP participants also reported significantly better quality of life and satisfaction with services at three months, with these effects sustained at all follow-up points.
Conclusion: The YCMAP intervention was shown to be beneficial in self-harm prevention among adolescents. Further research and replication of findings in diverse settings are recommended to strengthen the evidence base for this public health intervention.
Trial registration: ClinicalTrials.gov NCT04131179 and ISRCTN registry ISRCTN57325925.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the Foreign, Commonwealth and Development Office, the UK Medical Research Council, the National Institute for Health Research and the Wellcome Trust for the submitted work; NH has been a past trustee of the Pakistan Institute of Living and Learning, Abaseen Foundation UK, Lancashire Mind UK, and Manchester Global Foundation (MGF). He is an executive member of the Academic Faculty at the Royal College of Psychiatrists, London. He is a National Institute for Health Research (NIHR) senior investigator. He has attended educational events organised by various pharmaceutical industries. NC is CEO of the Pakistan Institute of Living and Learning, associate director of the Global Mental Health and Cultural Psychiatry Research Group, head of psychological medicine at the Remedial Centre Hospital, consultant psychiatrist at South City Hospital, consultant for Manchester Global Foundation and honorary professor of psychiatry, Dow University of Health Sciences. She is chief investigator and co-investigator for a number of research projects funded by various grant bodies such as the Medical Research Council, Welcome Trust, NIHR, and Global Challenges Research Fund. NC was previously a trustee of the Pakistan Institute of Living and Learning. IBC has given lectures or advice to Eli Lilly, Bristol Myers Squibb, Lundbeck, Astra Zeneca, and Janssen pharmaceuticals for which he or his employing institution have been reimbursed, outside the submitted work. The authors declare no conflicts of interest associated with this trial.
Figures

References
-
- WHO. Suicide worldwide in 2019: global health estimates. 2021. Available at: https://www.who.int/publications/i/item/9789240026643
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical